Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
about
Crizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyCrizotinib: from discovery to accelerated development to front-line treatmentTargeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsCIViC databaseFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceSecond- and third-generation ALK inhibitors for non-small cell lung cancerImplementing Genome-Driven Oncology.Use of big data in drug development for precision medicine.The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancerC3orf21 ablation promotes the proliferation of lung adenocarcinoma, and its mutation at the rs2131877 locus may serve as a susceptibility marker.Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Resisting Resistance: Targeted Therapies in Lung Cancer.ALK: a tyrosine kinase target for cancer therapy.Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphomaL1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung CancerALK gene alterations in cancer: biological aspects and therapeutic implications.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Emerging treatment for ALK-positive lung cancer.How might treatment of ALK-positive non-small cell lung cancer change in the near future?Clinician Perspectives on Current Issues in Lung Cancer Drug Development.The pharmacogenomics of drug resistance to protein kinase inhibitors.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.Targeting ALK: Precision Medicine Takes on Drug Resistance.Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.
P2860
Q26738381-0267B07C-A445-4C49-B316-AA8AD9931D2AQ26738384-78A28BE9-6813-4377-A428-E3BB8DBA6A85Q26738385-4700F55A-9E85-4BD2-A4D9-39E735497F12Q26738986-F5C2B0D6-BA09-4D57-873C-562BC1E5BF09Q26740329-6083F4E3-46E4-4F04-AD42-A736C4F0355CQ27612411-C2CDC973-0D69-4D72-89F3-3D657ECAD0A9Q28068643-9C4003D8-34CA-4950-A3F0-18CCE06AD5DCQ28071903-5C9C9EC7-10B7-410E-A17A-1790539AB11EQ28072496-F0D64DE5-6695-4498-874A-C6CAB5FF4A2DQ30235979-06B43591-C447-4794-8F0D-67647D62B284Q31115480-0EB580D2-433F-41EC-9291-176BA8CAB051Q33553447-3DAADB7E-F187-49B0-A04F-A72EFE1ED468Q33682922-C24E606E-8301-498C-9CEF-94C7253995C7Q33779505-FF835452-21F1-4608-9F90-FAE699D64ED3Q35979767-0A9EA4B5-3B6D-47BD-9567-32D7438DFF3BQ36114660-2E253E1A-04BF-4566-B66C-77447B67211BQ37388238-401892DF-7653-4B60-98EF-13A963A613A9Q37518624-FDF6E3C7-8180-49CF-BF1F-167DA9AB3E51Q37662209-2E90DBF4-20D1-4295-81F1-6C29CAD230F7Q37687313-2C7D99C7-40D2-4943-97D3-10762FD1A1D5Q37728989-6526E159-DEB5-4F82-B616-AA88912F43DDQ38631019-58D9E3D5-1336-445F-A747-A253CF7A9FC1Q38635259-231F6B23-142B-46B4-BBB7-D2B7E8369B88Q38663460-483F83D8-4104-4921-AEE2-7D3EBEBDBE8AQ38685481-CB8BFA1C-275F-4F1B-98C6-7E2B6346FCF2Q38735467-B9CA2A49-BEA6-4C3C-8345-FFCC89FAB60BQ38767006-B8EF286A-D7A5-4F8C-B637-DACB6D55CD18Q38792120-423B710A-C17A-4F59-B73F-E0DCF8AEAD0FQ38794422-F9E59040-2B5A-4F1E-B33B-A543E88BCAF4Q38805618-9C87ED19-F55B-42E9-AF69-4AE2F0CED58AQ38816700-E87E06FB-A940-4FD3-82EC-6443D5248A8BQ38819472-B17065B0-BAC0-440F-8E2B-1B52FD7C4D86Q38830389-C7DEDE1E-A54C-4822-BF92-6D0FB2D19031Q38892840-FC9D21D7-3B33-4DF3-9B91-E431B65FAA5DQ38952751-052B97F6-34DC-4763-ACB7-CF34941ECD93Q39007500-B084941F-83B7-42A6-8B11-A01A5C362FF9Q39028181-F05D184F-CC4D-4C04-83F3-5BA8BE3605C8Q39039088-A31F96A3-C421-4B9A-8D5D-AC3B4904F484Q39103431-D932EFA5-DB3D-4EDE-AF4A-EBAA6ADCD9C2Q39139953-B8CC0B0F-9992-4181-8127-808E37B8F8CC
P2860
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@ast
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@en
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@nl
type
label
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@ast
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@en
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@nl
altLabel
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
@en
Resensitization to Crizotinib by the LorlatinibALKResistance Mutation L1198F
@en
prefLabel
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@ast
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@en
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@nl
P2093
P2860
P50
P3181
P356
P1476
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
@en
P2093
A John Iafrate
Alexei Brooun
Alice T Shaw
Benjamin J Burke
Jeffrey A Engelman
Jennifer Logan
Justin F Gainor
Kate R Schultz
Leila Dardaei
Leonard P James
P2860
P3181
P356
10.1056/NEJMOA1508887
P407
P577
2016-01-07T00:00:00Z